Valeant Pharma (VRX) Reports Q3 EPS of $2.11
Tweet
Share
E-mail
Get Alerts VRX Hot Sheet
Price: $23.40 --0%
Financial Fact:
Income from continuing operations attributable to Valeant: 0.42
Today's EPS Names:
PLCE, COE, JVA, More
Financial Fact:
Income from continuing operations attributable to Valeant: 0.42
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Valeant Pharma (NYSE: VRX) reported Q3 EPS of $2.11, versus $1.43 reported last year. Revenue for the quarter came in at $2.06 billion, versus $1.54 billion reported last year.
Analysts were looking for EPS of $1.99.
Valeant sees FY14 cash EPS of $8.22 to $8.32 and Q4 EPS from $2.45 to $2.55. The company was previously looking for FY14 EPS of $7.90 to $8.10.
For earnings history and earnings-related data on Valeant Pharma (VRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nvidia pitches Vera CPU to Chinese clients with August delivery target
- Lennar Corp. (LEN) Misses Q2 EPS by 1c
- 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
